Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VistaGen Therapeutics's Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-37.28 Mil. Therefore, VistaGen Therapeutics's EV-to-EBIT ratio for today is -3.71.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, VistaGen Therapeutics's Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 was $-36.70 Mil. Therefore, VistaGen Therapeutics's EV-to-EBITDA ratio for today is -3.77.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, VistaGen Therapeutics's Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 was $1.51 Mil. Therefore, VistaGen Therapeutics's EV-to-Revenue ratio for today is 91.51.
VistaGen Therapeutics Enterprise Value Historical Data
The historical data trend for VistaGen Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Enterprise Value
14.48
11.02
41.53
24.39
285.33
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Enterprise Value
168.58
285.33
509.07
448.12
322.13
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Enterprise Value Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Enterprise Value falls into.
VistaGen Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
VistaGen Therapeutics's Enterprise Value for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics (NAS:VTGN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
VistaGen Therapeutics's current Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-37.28 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
VistaGen Therapeutics's EV-to-EBITDA for today is:
VistaGen Therapeutics's current Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.70 Mil.
VistaGen Therapeutics's current Enterprise Value is $138.36 Mil.
VistaGen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VistaGen Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.04(3.92%) Volume: 1,926,517 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
